Antisense & RNAi Therapeutics Market

Antisense & RNAi Therapeutics Market by Technology (RNA Interference [siRNA and miRNA], and Antisense RNA), Application (Oncology, Cardiovascular Diseases, Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, and Other), Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, and Other Delivery Methods), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1200
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 143
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global antisense & RNAi therapeutics market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the possibility of investigating gene function for illness management by controlling gene expression by the faulty gene, as well as R&D for the treatment of rare neurodegenerative disorders such as hereditary ATTR amyloidosis.

The therapeutic targeting of RNA is known as RNA medicine. In RNA medicine, two main techniques are used: double-stranded RNA-mediated interference (RNAi) and antisense oligonucleotides (ASO). In general, RNAi works by activating ribonucleases, which, in concert with other enzymes and complexes, coordinately breakdown the RNA once the initial RNA target has been broken into smaller pieces3. Antisense oligonucleotides bind to their target nucleic acid by Watson-Crick base pairing, inhibiting or altering gene expression through steric hindrance, splicing changes, target degradation initiation, and other mechanisms. RNAi is a naturally occurring mechanism that cells employ to control gene expression and can block genes from being translated into proteins.

Global Antisense & RNAi Therapeutics Market Summary

Furthermore, RNAi is employed in cells' innate immune response as a defensive mechanism against invading nucleic acids such as viruses and bacteria. The use of oligonucleotides to target mainly ribonucleic acids (RNA) for therapeutic purposes or in research investigations to clarify gene activities is referred to as RNA therapies. Because of their modes of action and chemical characteristics, oligonucleotides differ from other pharmacological modalities that target primarily proteins, such as small molecules and antibodies. Deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) are two types of nucleic acids (RNA). Although DNA is more durable, RNA has a wider range of structural variations, including non-coding RNAs, microRNA (miRNA), transfer RNA (tRNA), small interfering RNAs (siRNAs), ribosomal RNA (rRNA), and long-noncoding RNAs (lncRNAs).

Researchers have attempted to target RNA as our understanding of the broad diversity of RNAs grows, since more than 80% of the genome is believed to be transcribed. Non-coding RNAs such as miRNAs and siRNAs, which play crucial roles in the transfer of genetic information from DNA to protein, the end result of the fundamental dogma in biology1, are among these transcripts. RNA is now targeted using two methods: double-stranded RNA-mediated interference (RNAi) and antisense oligonucleotides (ASO). Both methods are now being tested in clinical trials for the treatment of RNAs implicated in illnesses including cancer and neurodegeneration.

Market Trends, Drivers, Restraints, and Opportunities

  • Antisense technology allows to regulate gene expression, and it's being promoted as a promising therapy for a variety of diseases this is projected to boost the market during the forecast period.
  • Antisense and RNAi therapies allow for extremely precise and efficient gene silencing and a large number of gene silencing medicines are in the late stages of research are anticipated to push the market growth in the coming years.
  • Increasing number of firms which are developing molecules based on antisense technology this is expected to drive the market growth during the forecast period.
  • Drug delivery to the nervous tissues to pass the blood-brain barrier is anticipated to hamper the market growth during the forecast period.
  • Harmful side effects caused by the use of antisense technology presents as key challenge that can hinder the market growth during the forecast period.
  • Increased focus on R&D investment for development of treatment of uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis and technological advancements are expected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global antisense & RNAi therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Antisense & RNAi Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Technology (RNA Interference [siRNA and miRNA], and Antisense RNA), Application (Oncology, Cardiovascular Diseases, Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, and Other), Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, and Other Delivery Methods)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Glaxo Smith Kline; Sanofi Aventis / Genzyme; Isis Pharmaceuticals/ Ionis Pharmaceutical; Arbutus Biopharma Ltd.; Silence Therapeutics; Bio-Path Holdings Inc.; Calando Pharmaceuticals; ICo Therapeutics; Quark Pharmaceuticals; Rexhan Pharmaceuticals; Biomarin/Prosensa; Regulus Therapeutics; Rxi Pharmaceuticals; Silenseed; Dicerna Pharmaceuticals; and Sirnaomics Inc.

 

Market Segment Insights

Antisense RNA segment is expected to account for a key share
Based on technology, the antisense & RNAi therapeutics market is bifurcated into RNA interference and antisense RNA. The RNA interference segment is further sub segmented into siRNA and miRNA. The antisense RNA segment is expected to account for a key share of the market during the forecast period owing to investigations have indicated that compounds developed using antisense technology are showing promise in the treatment of spinal muscular atrophy and amyotrophic lateral sclerosis. Furthermore, several antisense technologies and oligonucleotide compounds are also being studied for non-neurodegenerative diseases. For example, in Duchenne muscular dystrophy, antisense-mediated exon skipping.

Oncology segment is expected to hold a key share
Based on application, the antisense & RNAi therapeutics market is segmented into oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and other. The oncology segment is expected to hold a key share of the market during the forecast period owing to increasing need for the cure and prevention of illnesses such as cancer, HIV, and other diseases caused by mutating viruses is expected to impact oligonucleotide product usage rates. The field of oligonucleotide medicines is rapidly developing, as seen by the growing number of clinical trials. Ionis Pharmaceuticals, for example, has four compounds in the pipeline, two of which are authorized in the European Union and one in the United States. Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. have a large pipeline of cancer treatments that are projected to fuel the industry.

Furthermore, several businesses have engaged in research and development for nanocarriers to transport oligonucleotides for cancer treatment, which is predicted to aid cancer management. The toxicity of these oligonucleotides can be reduced by using nanocarriers. The fact that these nanoparticle systems are impacted by inter- and intra-tumor heterogeneity is a significant bottleneck. As a result, more efficient tumor targeting vectorization methods and multiple genes targeting oligonucleotide medicines are required. The demand for innovative and safer delivery techniques for the treatment of cancer and other viral diseases is likely to drive market expansion.

Global Antisense & RNAi Therapeutics Market By Application

Antisense & RNAi therapeutics is expected to expand at a significant CAGR
Based on route of administration, the antisense & RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other delivery methods. One of the most essential features of any genetically engineered molecule is the route of administration. The effectiveness of these molecules varies depending on the route of administration, the genetically modified molecule's vector, and the type of molecule to be injected. The majority of currently ongoing research involve attenuated virus particles or bacterial cells that are administered intravenously for therapy. One of the most essential features of any genetically engineered molecule is the route of administration. The effectiveness of these molecules varies depending on the route of administration, the genetically modified molecule's vector, and the type of molecule to be injected. The majority of currently ongoing research involve attenuated virus particles or bacterial cells that are administered intravenously for therapy.

Global Antisense & RNAi Therapeutics Market By Route of Administration

North America is anticipated to dominate
On the basis of regions, the antisense & RNAi therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to a number of RNAi therapies are already being developed. A number of biotechnology firms have made significant expenditures in the development of RNAi therapeutics. Big pharmaceutical companies have gone into cooperation or license arrangements with a number of smaller companies in an attempt to profit from the projected revenue increase in this industry during the projection period. One of the key partnerships that are substantially investing in antisense technology is AstraZeneca's collaboration with Ionis Pharmaceuticals. There have been several paths of therapy development utilizing RNAi since its discovery in, however the industry has grown extremely slowly over the last decade due to the difficulties in RNAi delivery techniques. The market has been re-infused with a significant potential for growth during the projection period due to the introduction of innovative nanotechnology-oriented approaches. A number of medication candidates now undergoing clinical trials have showed promising results and are moving forward in the development process. Assuming that such studies continue to yield favorable findings, the North American market is projected to see significant demand increase during the projection period.

Global Antisense & RNAi Therapeutics Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antisense & RNAi Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Antisense & RNAi Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Antisense & RNAi Therapeutics Market - Supply Chain
  4.5. Global Antisense & RNAi Therapeutics Market Forecast
     4.5.1. Antisense & RNAi Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Antisense & RNAi Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Antisense & RNAi Therapeutics Market Absolute $ Opportunity
5. Global Antisense & RNAi Therapeutics Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Antisense & RNAi Therapeutics Market Size and Volume Forecast by Applications
     5.3.1. Oncology
     5.3.2. Cardiovascular Diseases (CVDs)
     5.3.3. Respiratory Disorders
     5.3.4. Renal Diseases
     5.3.5. Neurodegenerative Disorders
     5.3.6. Genetic Disorders
     5.3.7. Infectious Diseases
     5.3.8. Other
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Antisense & RNAi Therapeutics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Antisense & RNAi Therapeutics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Antisense & RNAi Therapeutics Demand Share Forecast, 2019-2026
7. North America Antisense & RNAi Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Antisense & RNAi Therapeutics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Antisense & RNAi Therapeutics Market Size and Volume Forecast by Applications
     7.4.1. Oncology
     7.4.2. Cardiovascular Diseases (CVDs)
     7.4.3. Respiratory Disorders
     7.4.4. Renal Diseases
     7.4.5. Neurodegenerative Disorders
     7.4.6. Genetic Disorders
     7.4.7. Infectious Diseases
     7.4.8. Other
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Antisense & RNAi Therapeutics Demand Share Forecast, 2019-2026
8. Latin America Antisense & RNAi Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Antisense & RNAi Therapeutics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Antisense & RNAi Therapeutics Market Size and Volume Forecast by Applications
     8.4.1. Oncology
     8.4.2. Cardiovascular Diseases (CVDs)
     8.4.3. Respiratory Disorders
     8.4.4. Renal Diseases
     8.4.5. Neurodegenerative Disorders
     8.4.6. Genetic Disorders
     8.4.7. Infectious Diseases
     8.4.8. Other
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Antisense & RNAi Therapeutics Demand Share Forecast, 2019-2026
9. Europe Antisense & RNAi Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Antisense & RNAi Therapeutics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Antisense & RNAi Therapeutics Market Size and Volume Forecast by Applications
     9.4.1. Oncology
     9.4.2. Cardiovascular Diseases (CVDs)
     9.4.3. Respiratory Disorders
     9.4.4. Renal Diseases
     9.4.5. Neurodegenerative Disorders
     9.4.6. Genetic Disorders
     9.4.7. Infectious Diseases
     9.4.8. Other
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Antisense & RNAi Therapeutics Demand Share Forecast, 2019-2026
10. Asia Pacific Antisense & RNAi Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Antisense & RNAi Therapeutics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Antisense & RNAi Therapeutics Market Size and Volume Forecast by Applications
     10.4.1. Oncology
     10.4.2. Cardiovascular Diseases (CVDs)
     10.4.3. Respiratory Disorders
     10.4.4. Renal Diseases
     10.4.5. Neurodegenerative Disorders
     10.4.6. Genetic Disorders
     10.4.7. Infectious Diseases
     10.4.8. Other
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Antisense & RNAi Therapeutics Demand Share Forecast, 2019-2026
11. Middle East & Africa Antisense & RNAi Therapeutics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Antisense & RNAi Therapeutics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Antisense & RNAi Therapeutics Market Size and Volume Forecast by Applications
     11.4.1. Oncology
     11.4.2. Cardiovascular Diseases (CVDs)
     11.4.3. Respiratory Disorders
     11.4.4. Renal Diseases
     11.4.5. Neurodegenerative Disorders
     11.4.6. Genetic Disorders
     11.4.7. Infectious Diseases
     11.4.8. Other
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Antisense & RNAi Therapeutics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Antisense & RNAi Therapeutics Market: Market Share Analysis
  12.2. Antisense & RNAi Therapeutics Distributors and Customers
  12.3. Antisense & RNAi Therapeutics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Glaxo Smith Kline
     12.4.2. Sanofi Aventis / Genzyme
     12.4.3. Isis Pharmaceuticals/ Ionis Pharmaceuticals
     12.4.4. Arbutus Biopharma Ltd.
     12.4.5. Silence Therapeutics
     12.4.6. Bio-Path Holdings Inc.
     12.4.7. Calando Pharmaceuticals
     12.4.8.
Segments Covered in the Report
The global antisense & RNAi therapeutics market has been segmented on the basis of

Technology
  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA
Application
  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Other
Route of Administration
  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Other Delivery Methods
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Glaxo Smith Kline
  • Sanofi Aventis / Genzyme
  • Isis Pharmaceuticals/ Ionis Pharmaceuticals
  • Arbutus Biopharma Ltd.
  • Silence Therapeutics
  • Bio-Path Holdings Inc.
  • Calando Pharmaceuticals
  • ICo Therapeutics
  • Quark Pharmaceuticals
  • Rexhan Pharmaceuticals
  • Biomarin/Prosensa
  • Regulus Therapeutics
  • Rxi Pharmaceuticals
  • Silenseed
  • Dicerna Pharmaceuticals
  • Sirnaomics Inc.

Key players competing in the antisense & RNAi therapeutics market includes Glaxo Smith Kline; Sanofi Aventis / Genzyme; Isis Pharmaceuticals/ Ionis Pharmaceutical; Arbutus Biopharma Ltd.; Silence Therapeutics; Bio-Path Holdings Inc.; Calando Pharmaceuticals; ICo Therapeutics; Quark Pharmaceuticals; Rexhan Pharmaceuticals; Biomarin/Prosensa; Regulus Therapeutics; Rxi Pharmaceuticals; Silenseed; Dicerna Pharmaceuticals; and Sirnaomics Inc.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares.

Global Antisense & RNAi Therapeutics Market By Key Players

Buy Report